肿瘤位置作为pT3N0直肠癌术后辅助放疗的指征
该回顾性研究纳入2005年3月至2015年9月接受手术及辅助治疗的265例pT3N0直肠癌患者,按是否接受辅助放疗分组,比较总生存和无病生存。结果显示下段肿瘤患者中辅助放化疗组无病生存高于辅助化疗组,局部复发和远处转移率更低;上段肿瘤患者两组5年总生存和无病生存相似。多因素分析显示CEA和肿瘤位置是LRFS的独立预测因素,辅助放疗可预测下段直肠癌患者的DFS、LRFS和DMFS。
要点
- 下段pT3N0直肠癌患者中,辅助放化疗组无病生存高于辅助化疗组。
- 下段肿瘤接受辅助放疗者局部复发率和远处转移率更低。
- 上段肿瘤患者辅助化疗与辅助放化疗的5年总生存和无病生存相似。
核心结论
- 肿瘤位置可作为pT3N0直肠癌患者是否接受辅助放疗的指征。
研究设计与样本
- 回顾性研究,纳入2005年3月至2015年9月接受手术和辅助治疗的265例pT3N0直肠癌患者,按是否接受辅助放疗分为两组。
主要发现
- 下段肿瘤患者中,辅助放化疗组无病生存高于辅助化疗组,且接受辅助放疗者局部复发率和远处转移率更低。
- 上段肿瘤患者中,辅助化疗组与辅助放化疗组的5年总生存和无病生存相似。
- 多因素分析显示CEA和肿瘤位置均为LRFS的独立预测因素,辅助放疗可预测下段直肠癌患者的DFS、LRFS和DMFS。
关键数值与推荐
- 下段肿瘤:辅助放化疗组无病生存高于辅助化疗组,局部复发率和远处转移率更低。
- 上段肿瘤:辅助化疗组与辅助放化疗组的5年总生存和无病生存相似。
- 多因素分析:CEA和肿瘤位置是LRFS的独立预测因素;辅助放疗预测下段直肠癌的DFS、LRFS和DMFS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal care for pT3N0 rectal cancer remains controversial. And whether tumor location can be used to guide the administration of adjuvant radiotherapy for pT3N0 rectal cancer is not fully confirmed. The current study was designed to identify the benefit of adjuvant radiotherapy for pT3N0 rectal cancer. METHODS: We performed a retrospective study of 265 pT3N0 rectal cancer patients who were treated by surgery and adjuvant therapy from Mar. 2005 to Sept. 2015. All patients were divided into two groups according to receiving adjuvant radiotherapy or not. Overall survival (OS), disease-free survival (DFS) were compare between patients who did and did not receive adjuvant radiotherapy. Multivariate analysis was performed to explore clinical factors significantly associated with DFS, local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS). RESULTS: For patients with lower tumor, DFS in adjuvant chemo-radiotherapy group was higher than that in adjuvant chemotherapy group. Besides, the rates of local recurrence and distant metastasis were found lower in patients who did receive adjuvant radiotherapy than those who did not. For patients with upper tumor, the 5-year OS and DFS were similar between groups of adjuvant chemotherapy and adjuvant chemo-radiotherapy. Multivariable analysis indicated both the CEA and tumor location were independent predictors of LRFS. And adjuvant radiotherapy predicted the DFS, LRFS and DMFS in lower rectal cancer patients. CONCLUSION: Tumor location can serve as an indication for the administration of adjuvant radiotherapy in pT3N0 rectal cancer patients.
引用
- Peng HH, Zhou XH, Zhou TC, et al. Tumor location as an indication for adjuvant radiotherapy in pT3N0 rectal cancer after surgery. Radiat Oncol. 2019. PMID: 30651116. doi:10.1186/s13014-019-1206-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。